For example, murine-specific anti-TNFR2 antibody (TY101, 100 μg per mouse twice a week) was shown to have the capacity to increase the ratio of CD8+ T effectors (Teffs) to Tregs by preferentially reducing TNFR2-expressing Tregs in the tumor microenvironment [40]. The gene discussed is CD8A; the disease is neoplasm.